Agios Pharmaceuticals 주식 가격. AGIO - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

가격

34.02

매수가

33.01

매도가

35.56

거래량

0.00 일간 변동폭 0.00

26.19 52주 범위 62.58

market_cap

1.949B

전일 종가

34.02

개장가

최근 거래 시간

34.58

마지막 거래 시간

21:00:10

재정 규모

VWAP

평균 볼륨(3m)

906,508

발행 주식

57,296,167

배당수익률

주가수익률

-5.54

주당순이익(EPS)

-6.15

매출

26.82M

순이익

-352.09M

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' p... Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. 더 보기

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

www.agios.com

본부

Wilmington, Delaware, USA

설립됨

Agios Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker AGIO. The last closing price for Agios Pharmaceuticals was US$34.02. Over the last year, Agios Pharmaceuticals shares have traded in a share price range of US$ 26.19 to US$ 62.58.

Agios Pharmaceuticals currently has 57,296,167 shares in issue. The market capitalisation of Agios Pharmaceuticals is US$1.95 billion. Agios Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.54.

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

– Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusio...

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency...

Form 8-K - Current report

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in...

Form 4 - Statement of changes in beneficial ownership of securities

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

– FDA Accepted Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with...

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0.54	1.61290322581	33.48	34.86	31.95	728308	33.50877029	CS
4	-1.34	-3.78959276018	35.36	35.84	31.5607	635359	33.72948602	CS
12	-25.05	-42.407313357	59.07	62.45	31.3863	906508	38.25746984	CS
26	-11.39	-25.0825809293	45.41	62.58	31.3863	702430	42.96893534	CS
52	7.83	29.8969072165	26.19	62.58	26.19	716659	40.06474719	CS
156	5.44	19.0342897131	28.58	62.58	16.75	623308	30.96779296	CS
260	-18.98	-35.8113207547	53	62.58	16.75	645196	36.83730169	CS

AGIO - Frequently Asked Questions (FAQ)

What is the current Agios Pharmaceuticals share price?

The current share price of Agios Pharmaceuticals is US$ 34.02

How many Agios Pharmaceuticals shares are in issue?

Agios Pharmaceuticals has 57,296,167 shares in issue

What is the market cap of Agios Pharmaceuticals?

The market capitalisation of Agios Pharmaceuticals is USD 1.95B

What is the 1 year trading range for Agios Pharmaceuticals share price?

Agios Pharmaceuticals has traded in the range of US$ 26.19 to US$ 62.58 during the past year

What is the PE ratio of Agios Pharmaceuticals?

The price to earnings ratio of Agios Pharmaceuticals is -5.54

What is the cash to sales ratio of Agios Pharmaceuticals?

The cash to sales ratio of Agios Pharmaceuticals is 72.68

What is the reporting currency for Agios Pharmaceuticals?

Agios Pharmaceuticals reports financial results in USD

What is the latest annual turnover for Agios Pharmaceuticals?

The latest annual turnover of Agios Pharmaceuticals is USD 26.82M

What is the latest annual profit for Agios Pharmaceuticals?

The latest annual profit of Agios Pharmaceuticals is USD -352.09M

What is the registered address of Agios Pharmaceuticals?

The registered address for Agios Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Agios Pharmaceuticals website address?

The website address for Agios Pharmaceuticals is www.agios.com

Which industry sector does Agios Pharmaceuticals operate in?

Agios Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

기호	가격	볼륨
WOKWORK Medical Technology Group Ltd	US$ 4.95 (98.80%)	27.55M
FGENFibroGen Inc	US$ 0.9073 (61.44%)	44.02M
PPIAxs Astoria Inflation Sensitive ETF	US$ 24.54 (58.94%)	9
TCBSTexas Community Bancshares Inc	US$ 25.00 (56.25%)	6
ECBKECB Bancorp Inc	US$ 21.99 (53.67%)	10
CEADCEA Industries Inc	US$ 5.00 (-51.92%)	334
HFFGHF Foods Group Inc	US$ 1.21 (-48.73%)	1
SSKNStrata Skin Sciences Inc	US$ 1.51 (-47.57%)	2
ASRVAmeriServ Financial Inc	US$ 1.51 (-42.59%)	1
HWBKHawthorn Bancshares Inc	US$ 20.01 (-41.13%)	7
APTOAptose Biosciences Inc	US$ 0.223 (48.77%)	63.34M
ADTXAditxt Inc	US$ 0.1126 (-12.44%)	47.74M
FGENFibroGen Inc	US$ 0.9073 (61.44%)	44.04M
MNDRMobile health Network Solutions	US$ 0.4118 (25.05%)	31.1M
WOKWORK Medical Technology Group Ltd	US$ 4.95 (98.80%)	27.55M

기호

가격

볼륨

APTOAptose Biosciences Inc

US$ 0.223

(48.77%)

63.34M

ADTXAditxt Inc

US$ 0.1126

(-12.44%)

47.74M

FGENFibroGen Inc

US$ 0.9073

(61.44%)

44.04M

MNDRMobile health Network Solutions

US$ 0.4118

(25.05%)

31.1M

WOKWORK Medical Technology Group Ltd

US$ 4.95

(98.80%)

27.55M

$AGIO DD Notes ~ http://www.ddnotesmaker.com/AGIO

Topdown market analysis:
Market is _BULLISH_
Today is _UP_
Bullish Sector _BIOTECHNOLOGY_

bullish stock in this sector

$AGIO recent news/filings

## source: finance.yahoo.com

Wed, 29 Oct 2014 17:41:34 GMT ~ Nasdaq stocks posting largest percentage increases

read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-percentage-220237991--finance.html
*********************************************************

Wed, 29 Oct 2014 10:00:00 GMT ~ 'Mad Money' Lightning Round: I'm Sticking With Isis Pharmaceuticals

read full: http://www.thestreet.com/story/12861472/1/mad-money-lightning-round-im-sticking-with-isis-pharmaceuticals.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Tue, 28 Oct 2014 23:24:10 GMT ~ Lightning Round: GNC, Goldman and more

read full: http://www.cnbc.com/id/102128707?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=102128707
*********************************************************

Tue, 28 Oct 2014 18:12:59 GMT ~ Two biotech leaders to watch

read full: http://www.marketwatch.com/News/Story/Story.aspx?guid=D7CCEB70-396E-49E4-BD03-2CB82C69AFAC&siteid=yhoof2
*********************************************************

Mon, 27 Oct 2014 13:11:41 GMT ~ Agios Pharmaceuticals to Webcast Conference Call of Third Quarter 2014 Financial Results on November 7, 2014

[at noodls] - CAMBRIDGE, Mass., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that ...

read full: http://www.noodls.com/view/A2EF8BBB5ACD70924BD84BBCAE0F2381B1BCF76C
*********************************************************

$AGIO charts

basic chart ## source: stockcharts.com

basic chart ## source: stockscores.com

big daily chart ## source: stockcharts.com

big weekly chart ## source: stockcharts.com

$AGIO company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/AGIO/company-info
Ticker: $AGIO
OTC Market Place: Not Available
CIK code: not found
Company name: Agios Pharmaceuticals, Inc.
Incorporated In:

Business Description:

http://www.agios.com/

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

$AGIO share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$AGIO extra dd links

Company name: Agios Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=AGIO+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=AGIO+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=AGIO+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/news - http://finance.yahoo.com/q/h?s=AGIO+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/AGIO/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=AGIO+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/AGIO
DTCC (dtcc.com): http://search2.dtcc.com/?q=Agios+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Agios+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Agios+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/AGIO
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=AGIO&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=AGIO
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=AGIO+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=AGIO+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=AGIO
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=AGIO
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=AGIO+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/AGIO/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=AGIO+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/AGIO.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=AGIO
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/AGIO/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/AGIO/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/AGIO
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/AGIO
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/AGIO:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=AGIO
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=AGIO

$AGIO DD Notes ~ http://www.ddnotesmaker.com/AGIO

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Agios Pharmaceuticals Inc (AGIO)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

Agios Pharmaceuticals Inc 정보

AGIO 최신 뉴스

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Form 8-K - Current report

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Form 4 - Statement of changes in beneficial ownership of securities

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Form 8-K - Current report

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Form 4 - Statement of changes in beneficial ownership of securities

AGIO - Frequently Asked Questions (FAQ)

이동자

AGIO Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Agios Pharmaceuticals Inc (AGIO) 시세

Agios Pharmaceuticals Inc (AGIO)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

Agios Pharmaceuticals Inc 정보

AGIO 최신 뉴스

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Form 8-K - Current report

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Form 4 - Statement of changes in beneficial ownership of securities

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Form 8-K - Current report

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Form 4 - Statement of changes in beneficial ownership of securities

AGIO - Frequently Asked Questions (FAQ)

이동자

AGIO Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거